LPL Financial LLC Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)
LPL Financial LLC increased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 36.6% in Q4, owning 207,003 shares valued at approximately $9.9 million. Other investors also adjusted their positions, with 97.79% of the stock held by institutions. Halozyme's stock is currently trading down 3.5% at $59.77, with a market cap of $7.38 billion. The company reported a quarterly EPS of $1.19, exceeding estimates. Analysts have mixed ratings, with a consensus suggesting a buy rating and price targets ranging from $53 to $75.
LPL Financial LLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 36.6% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 207,003 shares of the biopharmaceutical company's stock after buying an additional 55,410 shares during the quarter. LPL Financial LLC owned approximately 0.16% of Halozyme Therapeutics worth $9,897,000 at the end of the most recent quarter.
Get Halozyme Therapeutics alerts:
Other large investors have also recently made changes to their positions in the company. Heck Capital Advisors LLC bought a new position in shares of Halozyme Therapeutics during the fourth quarter valued at approximately $29,000. CBIZ Investment Advisory Services LLC bought a new position in Halozyme Therapeutics in the 4th quarter worth $29,000. Smartleaf Asset Management LLC lifted its position in shares of Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 197 shares during the period. Venturi Wealth Management LLC purchased a new stake in shares of Halozyme Therapeutics in the 4th quarter worth about $69,000. Finally, Parkside Financial Bank & Trust boosted its stake in shares of Halozyme Therapeutics by 21.8% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after purchasing an additional 322 shares in the last quarter. 97.79% of the stock is currently owned by institutional investors.
Halozyme Therapeutics Trading Down 3.5 %
NASDAQ HALO opened at $59.77 on Friday. Halozyme Therapeutics, Inc. has a 12 month low of $37.73 and a 12 month high of $66.00. The company has a current ratio of 7.80, a quick ratio of 9.15 and a debt-to-equity ratio of 4.14. The stock's fifty day moving average price is $59.82 and its 200-day moving average price is $54.93. The stock has a market cap of $7.38 billion, a P/E ratio of 17.43, a P/E/G ratio of 0.42 and a beta of 1.32.
Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last announced its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 EPS for the quarter, beating the consensus estimate of $1.17 by $0.02. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million. Halozyme Therapeutics had a net margin of 43.74% and a return on equity of 157.78%. As a group, equities analysts forecast that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current fiscal year.
Insider Buying and Selling at Halozyme Therapeutics
In related news, SVP Michael J. Labarre sold 1,697 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $58.28, for a total value of $98,901.16. Following the sale, the senior vice president now owns 173,756 shares in the company, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Jeffrey William Henderson sold 10,000 shares of the business's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now owns 43,611 shares of the company's stock, valued at approximately $2,180,986.11. This represents a 18.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,200 shares of company stock worth $1,786,668. Insiders own 2.90% of the company's stock.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Benchmark restated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, February 20th. HC Wainwright restated a "buy" rating on shares of Halozyme Therapeutics in a research note on Thursday, March 6th. Piper Sandler lifted their price target on Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a research report on Friday, January 10th. Finally, Wells Fargo & Company decreased their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a report on Monday, January 13th. Four equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $62.78.
View Our Latest Stock Report on HALO
Halozyme Therapeutics Profile
(Free Report)Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
See Also
- Five stocks we like better than Halozyme Therapeutics
- How to Invest in the FAANG Stocks
- Archer Aviation’s Africa Deal Could Boost ACHR Stock
- How to Evaluate a Stock Before Buying
- Are Short Sellers Wrong About These 3 Semiconductor Stocks?
- Best Stocks Under $5.00
- Boeing Gets $50B in March Orders—Is BA Stock a Buy Now?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Halozyme Therapeutics Right Now?
Before you consider Halozyme Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Halozyme Therapeutics wasn't on the list.
While Halozyme Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
